Are we ready for global phase I studies? Wednesday, March 07, 2007 08:00 IST Dr Arun Bhatt Indian clinical trial industry is now entering into an exciting phase . The market has grown from $ 20 million in 2002 to $ 80-100 million in 2005. The market is continuing to grow at a rapid pace. This growth is spurred by the changes in IPR status and amendments in Schedule Y of clinical trials. These have made India more attractive to international pharma community. In 2004 the global CRO market was estimated to be $ 10 billion and was expected to grow at an annual rate of 14-16 % (ACRO website). The market segmentation was: Phase I 6.09%; Phase II- III 19.13%; Phase IIIb/IV 16.52%; Preclinical 17.39%; Central Lab 12.17%; Others 28. 7%. The 2007 estimate for CRO market is $14.4 billion. The 2007 market size for different phases (based on 2004 segmentation) is likely to be: Phase I : $ 0.87 million; Phase II- III : $ 2.7 billion; Phase IIIb/IV : $ 2.37 billion. The Indian CR...
Staying up to date with the clinical trials industry